Iambic Therapeutics Files for Nasdaq IPO as AI-Driven Drug Discovery Platform
核心洞察
Iambic Therapeutics (搜索) filed an S-1 on September 21, 2026 for a Nasdaq Global Select Market IPO under the ticker IAM.
Proceeds are earmarked for clinical development of IAM1363, IAM217 (搜索) and IAM-C1 plus working capital and general corporate purposes.
Lead asset IAM1363, an oral brain-penetrant pan-mutant HER2 (搜索) inhibitor, is in a Phase 1/1b basket study with a registrational trial planned as early as 2027.
Iambic Therapeutics (搜索) filed a registration statement with the SEC on September 21, 2026 for an initial public offering on the Nasdaq Global Select Market under the ticker "IAM." The San Diego-based company describes itself as an AI-native biopharma that integrates large-scale AI with automated chemistry and biology to design small-molecule drugs. J.P. Morgan, Jefferies, BofA Securities and Citigroup are lead underwriters.
The company's platform combines Enchant, a multimodal transformer model that predicts preclinical and clinical properties, NeuralPLexer, a generative structure engine for protein-ligand complexes, and a closed-loop automated lab for design-make-test cycles. Its lead program, IAM1363, is an oral, highly selective, pan-mutant, brain-penetrant HER2 (搜索) inhibitor in an ongoing Phase 1/1b basket study, with a registrational trial planned as early as 2027 subject to regulatory feedback. Two additional candidates, IAM217 (搜索) (a brain-penetrant allosteric KIF18A (搜索) inhibitor) and IAM-C1 (a selective dual CDK2 (搜索)/4 inhibitor), are preclinical, with IND submissions planned for Q4 2026.
Iambic reported $12.8 million in collaboration revenue for the six months ended June 30, 2026, and 2025 collaboration revenue of $9.4 million, up from $1.2 million in 2024. The company recorded a loss from operations of $53.5 million and a net loss of $50.1 million for the first half of 2026, and had 171 full-time employees as of September 18, 2026. Partners include AbbVie, Takeda, Lundbeck, NVIDIA (搜索), Lambda, Revolution Medicines, Jazz Pharmaceuticals and Bayer (搜索).
Source: TradingView